Cas:516474-08-1 1-Ethyl-2,3-dimethylimidazolium ethyl sulfate manufacturer & supplier

We serve Chemical Name:1-Ethyl-2,3-dimethylimidazolium ethyl sulfate CAS:516474-08-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-Ethyl-2,3-dimethylimidazolium ethyl sulfate

Chemical Name:1-Ethyl-2,3-dimethylimidazolium ethyl sulfate
CAS.NO:516474-08-1
Synonyms:1-Ethyl-2,3-dimethylimidazolium ethyl sulfate;MFCD06798161;Basionics(R) ST 67
Molecular Formula:C9H18N2O4S
Molecular Weight:250.31500
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:83.62000
Exact Mass:250.09900
LogP:1.20480

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like 1-Ethyl-2,3-dimethylimidazolium ethyl sulfate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Basionics(R) ST 67 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Ethyl-2,3-dimethylimidazolium ethyl sulfate Use and application,1-Ethyl-2,3-dimethylimidazolium ethyl sulfate technical grade,usp/ep/jp grade.


Related News: A new post-hoc analysis of pooled data from the TULIP phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures each, compared to placebo, in patients with moderate to severe systemic lupus erythematosus (SLE). 3-hydroxy-4-methoxy-butyric acid ethyl ester manufacturers But since the emergence of the Delta variant, the health ministry has twice reported a drop in the vaccine’s efficacy against infection and a slight decrease in its protection against severe disease. Octanoylnitrit suppliers Earlier this year, the company revealed it had broken ground on a 38,000-square-foot commercial cell therapy plant in Lexington, Massachusetts, which is about 10 miles from downtown Boston. Takeda says the new $84 million plant will be used to make cell therapies for cancers and other diseases. 13,14-dihydro-16,17-E-didehyro-17-(2-fluorophenyl)-17-trinor PGF1α vendor & factory.